FASN and breast carcinoma: This result shows that lapatinib suppressed both basal FASN activity and HRG-induced FASN activity (Figures 4A, B) and indicates that tyrosine phosphorylation of FASN plays a critical role in maintaining the physiological function of FASN in breast cancer cells.